Clinical Data Signs Distribution Agreement With Daiichi

Clinical Data announced that it has entered into a distribution agreement with Daiichi Pure Chemicals of Tokyo. Under this agreement Clinical Data will serve as the master distributor for a new diagnostic assay for the measurement of Prostate Specific Antigen, or PSA, a marker for the presence of prostate cancer. Daiichi's unique and proprietary assay technology allows PSA to be measured on Clinical Data's existing line of clinical chemistry analyzers and on most conventional clinical chemistry systems currently in use around the world.
Le Figaro